Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Christine McCarthy

Nurse Practitioner Albuquerque, NM Nurse Practitioner

NPI 1548598071 CMS profile 10538364

201 Cedar St Se, Albuquerque, NM 87106

Open in the dashboard

General payments

$893

51 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Christine McCarthy of Albuquerque, NM is reported in the CMS Open Payments database as having received $893 across 51 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 67th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $297 19
2024 General $229 14
2023 General $100 6
2022 General $110 6
2021 General $157 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christine McCarthy
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Christine McCarthy were reported at $297. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Christine McCarthy Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $157 $135 $40–$426 $132
2022 $110 $152 $48–$470 $149
2023 $100 $166 $54–$529 $160
2024 $229 $173 $55–$556 $164
2025 $297 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $207 13 payments
  2. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $192 19 payments
  3. Novartis Pharmaceuticals Corporation $174 7 payments
  4. Chiesi USA, Inc. $103 3 payments
  5. Salix Pharmaceuticals, a division of Bausch Health US, LLC $50 1 payment
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $50 1 payment
  7. Medtronic, Inc. $32 2 payments
  8. Amgen Inc. $29 2 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $20 1 payment
  10. Baxter Healthcare $19 1 payment
  11. Other $18 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $799 48 payments
  2. Education $94 3 payments
Products named General payments · program years 2021–2025
  1. LifeVest $192 19 payments
  2. FARXIGA $157 10 payments
  3. LEQVIO $123 4 payments
  4. KENGREAL $103 3 payments
  5. RELISTOR $50 1 payment
  6. OFEV $50 1 payment
  7. BRILINTA $50 3 payments
  8. CLEVIPREX $41 2 payments
  9. ENTRESTO $30 1 payment
  10. Repatha $29 2 payments
  11. Other $108 6 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

32

Median for Nurse Practitioner: 389

Drug cost

$417

Median for Nurse Practitioner: $21,885

Branded share of claims

100%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clopidogrel Clopidogrel Bisulfate Brand 20 $369
Isosorbide Mononitrate Er Isosorbide Mononitrate Brand 12 $48

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 5 billing codes

Paid by Medicare

$1,707

Medicare's payments for the services billed

Medicare patients

28

Average age 76

Services billed

31

17 women, 11 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 61%
Ischemic heart disease 61%
Arthritis 54%
Diabetes 50%
Atrial fibrillation 50%
Chronic kidney disease 50%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KENGREAL
  • CHIESI USA, INC. $72
$72 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $62
$62 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $31
$31 — —
Repatha
  • Amgen Inc. $14
$14 — —
CLEVIPREX
  • CHIESI USA, INC. $10
$10 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

51 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in New Mexico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record